Why the study?
Venous thromboembolism is common in cancer patients, carrying risks of recurrence, bleeding, cancer treatment interruption, and hospitalization, making thromboprophylaxis during chemotherapy of potential clinical value.
Do direct oral anticoagulants prevent venous thromboembolism in ambulatory patients with cancer receiving chemotherapy?
Do direct oral anticoagulants prevent venous thromboembolism in ambulatory patients with cancer receiving chemotherapy?
Discusses the potential clinical value of DOACs for preventing venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Supports considering direct oral anticoagulants for VTE prevention in ambulatory cancer patients; extends randomized evidence to outpatient chemotherapy settings.
Patients with cancer commonly have a venous thromboembolism during the course of their disease.1 Venous thromboembolism in these patients leads to a high risk of recurrence and bleeding related to anticoagulant therapy.2 Furthermore, venous thromboembolism exposes patients with cancer to the risk of interruption of cancer treatment and may lead to otherwise unnecessary hospitalization. For these reasons, prevention of venous thromboembolism in ambulatory patients with cancer who are receiving chemotherapy is of potential clinical value. In two large, randomized, placebo-controlled trials3,4 and a comprehensive meta-analysis,5 all involving ambulatory patients with different types of metastatic or locally advanced solid cancer who . . .
No takes yet. Share an insight, caveat, or question.
Giancarlo Agnelli (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: